ガイドライン

(旧版)前立腺癌診療ガイドライン 2006年版

書誌情報
第1章 疫学

 
参考文献

1) Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49:33-64.
2) がんの統計‘03: 悪性新生物年齢調整罹患率,主要部位別・年次別(昭和50年~平成10年):http://www.ncc.go.jp/jp/statistics/2003/data08.pdf :accessed on July 27, 2004.
3) 大野ゆう子,中村 隆,大島 明,他:日本のがん罹患の将来推計.がん・統計白書-罹患/死亡/予後-2004(大島 明,黒石哲生,田島和雄,編).篠原出版新社; 2004.p.201-17.
4) がんの統計‘03:悪性新生物年齢調整死亡率,主要部位別・年次別(昭和25年~平成13年):http://www.ncc.go.jp/jp/statistics/2003/data05.pdf :accessed on July 27, 2004.
5) 黒石哲生,広瀬かおる,田島和雄,他:日本のがん死亡の将来予測.がん・統計白書-罹患/死亡/予後-2004(大島明,黒石哲生,田島和雄,編).篠原出版新社;2004.p.219-34.
6) Yatani R, Chigusa I, Akazaki K, et al. Geographic pathology of latent prostatic carcinoma. Int J Cancer. 1982;29:611-6.
7) Etzioni R, Cha R, Feuer EJ, et al. Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol. 1998;148:775-85.
8) 白石泰三,他:前立腺ラテント癌.前立腺癌診療マニュアル,前立腺研究財団,金原出版;1995.p.13-24.
9) 渡辺 泱:前立腺癌の自然史.前立腺癌診療マニュアル,前立腺研究財団,金原出版,1995.p.1-12.
10) 伊藤一人,山本 巧,大井 勝,他:前立腺集団検診受診者における国際前立腺症状スコアー(I-PSS)の傾向とQOL indexとの関係.泌尿器外科.2001;14:868-71.
11) 福多史昌,舛森直哉,田中吉則,他:下部尿路症状を主訴とする受診症例における前立腺癌発見率.臨床泌尿器科.2005;59:133-8.
12) Lepor H, Owens RS, Rogenes V, et al. Detection of prostate cancer in males with prostatism. Prostate. 1994;25:132-40.
13) Steinberg GD, Carter BS, Beaty TH, et al. Family history and the risk of prostate cancer. Prostate. 1990;17:337-47.
14) Giovannucci E, Rimm EB, Colditz GA, et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst. 1993;85:1571-9.
15) 中田誠司,他:日本及び世界における前立腺癌死亡と食摂取様式の相関分析.癌の臨床.1994;40:831-6.
16) Hebert JR, Hurley TG, Olendzki BC, et al. Nutritional and socioeconomic factors in relation to prostate cancer mortality:a cross-national study. J Natl Cancer Inst. 1998;90:1637-47.
17) Eichholzer M, Stahelin HB, Ludin E, et al. Smoking, plasma vitamins C, E, retinol, and carotene, and fatal prostate cancer:seventeen-year follow-up of the prospective Basel study. Prostate. 1999;38:189-98.
18) Clark LC, Dalkin B, Krongrad A, et al. Decreased incidence of prostate cancer with selenium supplementation:results of a double-blind cancer prevention trial. Br J Urol. 1998;81:730-4.
19) Hartman TJ, Albanes D, Pietinen P, et al. The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev. 1998;7:335-40.
20) Smith RA, Cokkinides V, Eyre HJ, et al. American Cancer Society guidelines for the early detection of cancer, 2004. CA Cancer J Clin. 2004;54:41-52.
21) Prostate-specific antigen(PSA)best practice policy. American Urological Association(AUA). Oncology(Williston Park). 2000;14:267-72, 277-8, 280 passim.
22) Recommendations and Rationale. Screening for Prostate Cancer:U. S. Preventive Services Task Force(USPSTF): http://www.ahrq.gov/clinic/3rduspstf/prostatescr/prostaterr.htm :accessed on November 12, 2004.
23) Harris R, Lohr KN.:Screening for prostate cancer:an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:917-29.
24) Roberts RO, Bergstralh EJ, Katusic SK, et al. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J Urol. 1999;161:529-33.
25) Meyer F, Moore L, Bairati I, et al. Downward trend in prostate cancer mortality in Quebec and Canada. J Urol. 1999;161:1189-91.
26) Bartsch G, Horninger W, Klocker H, et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology. 2001;58:417-24.
27) Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian(PLCO)Cancer Screening Trial. Control Clin Trials. 2000:21(6 Suppl):273S-309S.
28) Schröder FH, Denis LJ, Roobol M, et al. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int. 2003;92 suppl 2:1-13.
29) 財団法人 前立腺研究財団,前立腺検診協議会:人間ドック健診における前立腺検査調査(1989年~1999年)・前立腺集団検診全国集計(1986年~1999年).泌尿器外科.2003;16:1023-38.
30) Kubota Y, Ito K, Imai K, et al. Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities. Prostate. 2002;50:262-9.
31) Ito K, Yamamoto T, Suzuki K, et al. The risk of rapid prostate specific antigen increase in men with baseline prostate specific antigen 2.0ng/ml or less. J Urol. 2004;171:656-60.
32) Ito K, Yamamoto T, Ohi M, et al. Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0ng/ml or less. Prostate. 2003;57:8-13.
33) Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan:2000 report from the Japanese Urological Association. Int J Urol. 2005;12:46-61.

書誌情報